Total Payments
$85,579
2024 Payments
$7,624
Companies
10
Transactions
148
Medicare Patients
1,816
Medicare Billing
$417,750
Payment Breakdown by Category
Research$43,335 (50.6%)
Consulting$30,436 (35.6%)
Travel$9,865 (11.5%)
Food & Beverage$1,849 (2.2%)
Education$94.25 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $43,335 | 75 | 50.6% |
| Consulting Fee | $30,436 | 10 | 35.6% |
| Travel and Lodging | $9,865 | 33 | 11.5% |
| Food and Beverage | $1,849 | 29 | 2.2% |
| Education | $94.25 | 1 | 0.1% |
Payments by Type
Research
$43,335
75 transactions
General
$42,245
73 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk AS | $42,482 | 72 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $16,205 | 26 | $0 (2022) |
| Relypsa, Inc. | $13,758 | 20 | $0 (2019) |
| AKEBIA THERAPEUTICS INC | $7,286 | 6 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $4,133 | 9 | $0 (2018) |
| Gilead Sciences, Inc. | $1,135 | 11 | $0 (2019) |
| ZOLL Medical Corporation | $338.33 | 1 | $0 (2024) |
| Amgen Inc. | $124.71 | 1 | $0 (2018) |
| Bayer HealthCare Pharmaceuticals Inc. | $102.12 | 1 | $0 (2021) |
| Keryx Biopharmaceuticals, Inc. | $16.19 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,624 | 7 | AKEBIA THERAPEUTICS INC ($7,286) |
| 2023 | $21,150 | 29 | Novo Nordisk AS ($21,150) |
| 2022 | $27,895 | 48 | Novo Nordisk AS ($21,050) |
| 2021 | $102.12 | 1 | Bayer HealthCare Pharmaceuticals Inc. ($102.12) |
| 2020 | $4,638 | 3 | AstraZeneca Pharmaceuticals LP ($4,638) |
| 2019 | $12,727 | 30 | Relypsa, Inc. ($6,871) |
| 2018 | $1,722 | 18 | Relypsa, Inc. ($1,148) |
| 2017 | $9,721 | 12 | Relypsa, Inc. ($5,738) |
All Payment Transactions
148 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/27/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Consulting Fee | Cash or cash equivalent | $6,615.00 | General |
| Category: Nephrology | ||||||
| 11/27/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Travel and Lodging | Cash or cash equivalent | $190.95 | General |
| Category: Nephrology | ||||||
| 11/16/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $67.04 | General |
| Category: Nephrology | ||||||
| 11/16/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $47.08 | General |
| Category: Nephrology | ||||||
| 11/16/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: Nephrology | ||||||
| 11/15/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Travel and Lodging | In-kind items and services | $344.60 | General |
| Category: Nephrology | ||||||
| 01/01/2024 | ZOLL Medical Corporation | Defibrillator (Medical Supply) | Consulting Fee | Cash or cash equivalent | $338.33 | General |
| Category: Resuscitation | ||||||
| 12/08/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $900.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 11/30/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $875.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 11/09/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $750.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 10/19/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $650.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 10/13/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $925.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 10/06/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $625.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 09/14/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $1,825.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 08/10/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $750.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 08/10/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $400.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 07/20/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $1,875.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 07/20/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $250.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 07/13/2023 | Novo Nordisk AS | Wegovy (Drug) | — | Cash or cash equivalent | $600.00 | Research |
| Study: EX9536-4388 • Category: Obesity | ||||||
| 06/22/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $775.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 06/15/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $625.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 06/08/2023 | Novo Nordisk AS | Wegovy (Drug) | — | Cash or cash equivalent | $375.00 | Research |
| Study: EX9536-4388 • Category: Obesity | ||||||
| 05/11/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $600.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 05/11/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $250.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 05/05/2023 | Novo Nordisk AS | Wegovy (Drug) | — | Cash or cash equivalent | $750.00 | Research |
| Study: EX9536-4388 • Category: Obesity | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NN9535-4321 | Novo Nordisk AS | $20,525 | 24 |
| EX9924-4473 | Novo Nordisk AS | $13,000 | 22 |
| EX9536-4388 | Novo Nordisk AS | $8,675 | 18 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | Gilead Sciences, Inc. | $1,135 | 11 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 456 | 919 | $414,628 | $96,392 |
| 2022 | 10 | 405 | 807 | $414,006 | $96,468 |
| 2021 | 12 | 438 | 845 | $455,421 | $105,472 |
| 2020 | 11 | 517 | 1,124 | $600,994 | $119,418 |
Total Patients
1,816
Total Services
3,695
Medicare Billing
$417,750
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 47 | 153 | $167,076 | $40,688 | 24.4% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2023 | 48 | 185 | $67,155 | $11,691 | 17.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 73 | 170 | $29,580 | $9,727 | 32.9% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 77 | 164 | $55,760 | $8,750 | 15.7% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 20 | 37 | $32,597 | $8,244 | 25.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 35 | 49 | $12,250 | $4,364 | 35.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 41 | 41 | $13,448 | $3,852 | 28.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 21 | 21 | $10,290 | $2,554 | 24.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 18 | 18 | $8,748 | $2,373 | 27.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 30 | 32 | $8,160 | $1,849 | 22.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 30 | 33 | $5,676 | $1,418 | 25.0% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 16 | 16 | $3,888 | $880.04 | 22.6% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 56 | 207 | $226,044 | $55,526 | 24.6% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 91 | 211 | $71,740 | $11,649 | 16.2% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 21 | 32 | $28,192 | $7,355 | 26.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 60 | 109 | $18,966 | $5,775 | 30.4% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2022 | 30 | 85 | $30,855 | $5,260 | 17.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 26 | 35 | $8,750 | $2,683 | 30.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 25 | 25 | $8,272 | $2,574 | 31.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 53 | 58 | $9,976 | $2,482 | 24.9% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 21 | 22 | $5,346 | $1,618 | 30.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 22 | 23 | $5,865 | $1,548 | 26.4% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 67 | 227 | $247,884 | $59,217 | 23.9% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 104 | 218 | $74,120 | $12,334 | 16.6% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2021 | 22 | 34 | $29,954 | $7,390 | 24.7% |
About John Middleton
John Middleton is a Nephrology healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1033293923.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, John Middleton has received a total of $85,579 in payments from pharmaceutical and medical device companies, with $7,624 received in 2024. These payments were reported across 148 transactions from 10 companies. The most common payment nature is "" ($43,335).
As a Medicare-enrolled provider, Middleton has provided services to 1,816 Medicare beneficiaries, totaling 3,695 services with total Medicare billing of $417,750. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Durham, NC
- Active Since 10/25/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1033293923
Products in Payments
- Ozempic (Drug) $20,525
- Veltassa (Drug) $13,758
- Rybelsus (Drug) $13,000
- LOKELMA (Drug) $12,212
- Wegovy (Drug) $8,675
- Vafseo (Drug) $7,286
- TOLVAPTAN (Drug) $4,133
- Defibrillator (Medical Supply) $338.33
- Repatha (Biological) $124.71
- Kerendia (Drug) $102.12
- Auryxia (Drug) $16.19
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Durham
Patrick Pun, Md, MD
Nephrology — Payments: $40,693
Nephrology $40,693
Dr. Charles Cooperberg, Md, MD
Nephrology — Payments: $10,378
Nephrology $10,378
Dr. John Musgrove, Md, MD
Nephrology — Payments: $5,918
Nephrology $5,918
Dr. Rasheeda Hall, M.d., M.b.a, M.D., M.B.A
Nephrology — Payments: $5,343
Nephrology $5,343
Dr. Samuel Shaikewitz, Md, MD
Nephrology — Payments: $4,794
Nephrology $4,794
Vinaya Rao, Md, MD
Nephrology — Payments: $4,544
Nephrology $4,544